369 related articles for article (PubMed ID: 15538740)
1. Fibroblast growth factor 17 is over-expressed in human prostate cancer.
Heer R; Douglas D; Mathers ME; Robson CN; Leung HY
J Pathol; 2004 Dec; 204(5):578-86. PubMed ID: 15538740
[TBL] [Abstract][Full Text] [Related]
2. FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease.
Dorkin TJ; Robinson MC; Marsh C; Bjartell A; Neal DE; Leung HY
Oncogene; 1999 Apr; 18(17):2755-61. PubMed ID: 10348350
[TBL] [Abstract][Full Text] [Related]
3. FGF17 is an autocrine prostatic epithelial growth factor and is upregulated in benign prostatic hyperplasia.
Polnaszek N; Kwabi-Addo B; Wang J; Ittmann M
Prostate; 2004 Jun; 60(1):18-24. PubMed ID: 15129425
[TBL] [Abstract][Full Text] [Related]
4. aFGF immunoreactivity in prostate cancer and its co-localization with bFGF and FGF8.
Dorkin TJ; Robinson MC; Marsh C; Neal DE; Leung HY
J Pathol; 1999 Dec; 189(4):564-9. PubMed ID: 10629559
[TBL] [Abstract][Full Text] [Related]
5. The significance of LMO2 expression in the progression of prostate cancer.
Ma S; Guan XY; Beh PS; Wong KY; Chan YP; Yuen HF; Vielkind J; Chan KW
J Pathol; 2007 Feb; 211(3):278-85. PubMed ID: 17167821
[TBL] [Abstract][Full Text] [Related]
6. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate.
Steiner GE; Newman ME; Paikl D; Stix U; Memaran-Dagda N; Lee C; Marberger MJ
Prostate; 2003 Aug; 56(3):171-82. PubMed ID: 12772186
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor-1 transcriptionally induces membrane type-1 matrix metalloproteinase expression in prostate carcinoma cell line.
Udayakumar TS; Nagle RB; Bowden GT
Prostate; 2004 Jan; 58(1):66-75. PubMed ID: 14673954
[TBL] [Abstract][Full Text] [Related]
8. Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer.
West AF; O'Donnell M; Charlton RG; Neal DE; Leung HY
Br J Cancer; 2001 Aug; 85(4):576-83. PubMed ID: 11506499
[TBL] [Abstract][Full Text] [Related]
9. Keratinocyte growth factor expression in hormone insensitive prostate cancer.
Leung HY; Mehta P; Gray LB; Collins AT; Robson CN; Neal DE
Oncogene; 1997 Aug; 15(9):1115-20. PubMed ID: 9285567
[TBL] [Abstract][Full Text] [Related]
10. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
11. Expression of adrenomedullin and peptide amidation activity in human prostate cancer and in human prostate cancer cell lines.
Rocchi P; Boudouresque F; Zamora AJ; Muracciole X; Lechevallier E; Martin PM; Ouafik L
Cancer Res; 2001 Feb; 61(3):1196-206. PubMed ID: 11221851
[TBL] [Abstract][Full Text] [Related]
12. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS
Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417
[TBL] [Abstract][Full Text] [Related]
13. Exogenous fibroblast growth factors maintain viability, promote proliferation, and suppress GADD45alpha and GAS6 transcript content of prostate cancer cells genetically modified to lack endogenous FGF-2.
Shain SA
Mol Cancer Res; 2004 Nov; 2(11):653-61. PubMed ID: 15561781
[TBL] [Abstract][Full Text] [Related]
14. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer.
Das S; Roth CP; Wasson LM; Vishwanatha JK
Prostate; 2007 Oct; 67(14):1550-64. PubMed ID: 17705178
[TBL] [Abstract][Full Text] [Related]
15. Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines.
Dizeyi N; Bjartell A; Nilsson E; Hansson J; Gadaleanu V; Cross N; Abrahamsson PA
Prostate; 2004 May; 59(3):328-36. PubMed ID: 15042609
[TBL] [Abstract][Full Text] [Related]
16. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia.
Soulitzis N; Karyotis I; Delakas D; Spandidos DA
Int J Oncol; 2006 Aug; 29(2):305-14. PubMed ID: 16820871
[TBL] [Abstract][Full Text] [Related]
17. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer.
Zhigang Z; Wenlv S
Jpn J Clin Oncol; 2004 Jul; 34(7):414-9. PubMed ID: 15342669
[TBL] [Abstract][Full Text] [Related]
18. Expression analysis and clinical utility of L-Dopa decarboxylase (DDC) in prostate cancer.
Avgeris M; Koutalellis G; Fragoulis EG; Scorilas A
Clin Biochem; 2008 Oct; 41(14-15):1140-9. PubMed ID: 18586020
[TBL] [Abstract][Full Text] [Related]
19. The relationship of cathepsin B and stefin A mRNA localization identifies a potentially aggressive variant of human prostate cancer within a Gleason histologic score.
Sinha AA; Quast BJ; Korkowski JC; Wilson MJ; Reddy PK; Ewing SL; Sloane BF; Gleason DF
Anticancer Res; 1999; 19(4B):2821-9. PubMed ID: 10652560
[TBL] [Abstract][Full Text] [Related]
20. Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development.
Ishiguro H; Nakaigawa N; Miyoshi Y; Fujinami K; Kubota Y; Uemura H
Prostate; 2005 Jun; 64(1):92-100. PubMed ID: 15666359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
